Literatur
[1] Bingel U, Enck P, Rief W, Schedlowski M. Avoiding nocebo effects to optimize treatment outcome. JAMA 2014;312:693-694
[2] Webster RK, Weinman J, Rubin GJ. A Systematic Review of Factors That Contribute to Nocebo Effects. Health Psychology 2016;35:1334-1355
[3] Horing B, Weimer K, Muth ER, Enck P. Prediction of placebo responses: a systematic review of the literature. Frontiers Psychol 2014;5:1079
[4] Enck P, Klosterhalfen S. The Placebo and Nocebo Responses in Clinical Trials in Inflammatory Bowel Diseases. Front Pharmacol 2021;12:641436
[5] Enck P, Klosterhalfen S. Placebo Responses and Placebo Effects in Functional Gastrointestinal Disorders. Front Psychiatry 2020;11:797
[6] Enck P, Klosterhalfen S. Placebos and the Placebo Effect in Drug Trials. Handb exp pharmacol 2019;260:399-431
[7] Hauser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Deutsches Arzteblatt international 2012;109:459-65.
[8] Webster RK, Weinman J, Rubin GJ. Medicine-related beliefs predict attribution of symptoms to a sham medicine: A prospective study. Br J Health Psychol 2018;23:436-454
[9] Faasse K, Gamble G, Cundy T, Petrie KJ. Impact of television coverage on the number and type of symptoms reported during a health scare: a retrospective pre-post observational study. BMJ open 2012;2(4)
[10] Liodden I, Pripp AH, Norheim AJ. Placebo by proxy expectations toward acupuncture change over time: a survey comparing parental expectations to acupuncture pre- and postoperatively. BMC complementary and alternative medicine 2018;18:183
[11] Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Archives of Internal Medicine 2006;166:155-160
[12] Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017;389:2473-2481
[13] Tobert JA. Statins - Good drugs, not so good reputation. International Journal of Cardiology 2018;262:28-29
[14] Khan S, Holbrook A, Shah BR. Does Googling lead to statin intolerance? International Journal of Cardiology 2018;262:25-27
[15] Stolshek BS, Wade S, Mutebi A, De AP, Wade RL, Yeaw J. Two-year adherence and costs for biologic therapy for rheumatoid arthritis. American Journal of Managed Care 2018;24:315-321
[16] Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S et al. Policies for biosimilar uptake in Europe: An overview. PloS one 2017;12:e0190147
[17] Peterson J, Budlong H, Affeldt T, Skiermont K, Kyllo G, Heaton A. Biosimilar Products in the Modern U.S. Health Care and Regulatory Landscape. Journal of Managed Care & Specialty Pharmacy 2017;23:1255-1259
[18] Rezk MF, Pieper B. Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect. Rheumatol ther 2017;4:209-218
[19] Rezk MF, Pieper B. To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars. Advances in Therapy 2018;35:749-753
[20] Pineles D, Malter L, Liang PS, Arsuaga A, Bosworth B, Hudesman DP et al. The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease. European Journal of Clinical Pharmacology 2018;74:1361-1362
[21] Yoo DH, Choe JY, Shim SC, Suh CH. Switching to biosimilars in the treatment of rheumatic diseases. Expert review of Clinical Immunology 2018;14:557-571
[22] Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Advances in therapy 2017;33:2160-2172
[23] Webster RK, Weinman J, Rubin GJ. People‘s Understanding of Verbal Risk Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to 65-Year-Olds in England. Drug safety 2017;40:743-754
[24] Webster RK, Weinman J, Rubin GJ. How does the side-effect information in patient information leaflets influence peoples‘ side-effect expectations? A cross-sectional national survey of 18- to 65-year-olds in England. Health expectations 2017;20:1411-1420
[25] Irving G, Neves AL, Dambha-Miller H, Oishi A, Tagashira H, Verho A, Holden J. International variations in primary care physician consultation time: a systematic review of 67 countries. BMJ open 2017:e017902
0 Kommentare
Das Kommentieren ist aktuell nicht möglich.